#USA #BioLife Solutions #Maple Grove #Peli BioThermal #Evo

Peli BioThermal Expands Cold Chain Solutions with Evo Acquisition

In a significant move to bolster its leadership in temperature-controlled logistics, Peli BioThermal has officially announced the acquisition of Evo from BioLife Solutions. This strategic acquisition, revealed on October 7, 2025, is set to enhance Peli BioThermal's extensive portfolio of products, services, and cutting-edge technology suited for the pharmaceutical and biopharmaceutical sectors.

Strengthening Cold Chain Capabilities

With the inclusion of Evo's advanced offerings, which feature cryogenic shippers and the evoIS® technology platform, Peli BioThermal is better positioned to meet the escalating demands of the Cell and Gene Therapy (C> therapy) market. The ability to provide solutions that ensure cryogenic transport is essential for the timely delivery of life-saving treatments to patients, emphasizing the growth potential in this specialized area.

The addition of Evo not only enriches Peli BioThermal’s current offerings but also provides an opportunity to engage new customers across various pharmaceutical and clinical supply chains. As the need for reliable cold chain solutions continues to rise, the access to Evo products is expected to deliver amplified value, speed, and integration to existing and future clients.

A Commitment to Innovation

Peli BioThermal's CEO, Sam Herbert, remarked on the acquisition, stating, "The addition of Evo is a strategic step forward that rounds out our solutions portfolio and reinforces our commitment to solving our customers' toughest cold chain challenges." This initiative underlines the company’s focus on expanding its service offerings and enhancing customer support across diverse markets.

Evo's existing clientele are set to benefit from an easier integration process, as they will now source their logistics solutions through Peli BioThermal. This integration is anticipated to accelerate product development and innovation, establishing a more extensive customer support network.

Meeting Critical Industry Needs

Evo's ability to provide specialized cryogenic solutions aligns perfectly with the rigorous standards of the Cell and Gene Therapy market, where precision, reliability, and flexibility are paramount for ensuring successful product transport. The acquisition is expected to foster innovative solutions that can adapt to the shifting needs of the life sciences landscape.

Future Growth and Development

This transaction marks the second acquisition for Peli BioThermal following its acquisition by Platinum Equity, signaling a robust commitment to growth in the temperature-controlled logistics domain. Platinum Equity’s Co-President, Jacob Kotzubei, articulated the importance of Evo in allowing Peli BioThermal to deepen existing relationships with current customers while tapping into new, high-growth markets.

The integration of Evo is expected to yield enhanced solutions, such as Peli BioThermal’s flagship product lines including Crēdo™ reusable shippers and the recently launched Crēdo Vault™ bulk shipper. Clients will now have added flexibility when selecting products tailored to their needs—be it sustainability, operational simplicity, or performance.

The operations team in Bruce Township, Michigan, that was previously part of Evo will remain intact, ensuring the preservation of expertise and continuity in customer support. This move will leverage Peli BioThermal’s global resources to drive further growth and innovation.

Looking Ahead

As Peli BioThermal prepares to merge Evo's capabilities into its existing framework, industry observers are keen to see how this acquisition will impact the cold chain logistics landscape. The goal is not only to satisfy current market demands but also to anticipate future needs, ensuring Peli BioThermal remains at the forefront of this vital sector.

To discover more about Peli BioThermal's enhanced offerings and how they support the logistics of Cell and Gene Therapy, visit www.pelibiothermal.com.